Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Influenza A (H1N1) virus infection complicated by checkpoint inhibitor pneumonitis: A case report.

Created on 17 Oct 2026

Authors

Yifan Cheng, Huiying Zhao, Youzhong An

Published in

Medicine. Volume 105. Issue 42. Pages e51109. Oct 16, 2026.

Abstract

Checkpoint inhibitor pneumonitis (CIP) is a common, potentially severe adverse event in cancer patients receiving neoadjuvant immunotherapy, with glucocorticoids as the standard first-line treatment. Traditionally, glucocorticoids are avoided in confirmed viral pneumonia because they may delay viral clearance and increase secondary infection risk. No standardized strategy is available for managing concurrent CIP and viral pneumonia, and inappropriate treatment can lead to irreversible clinical deterioration.
Following neoadjuvant immunotherapy, the patient developed concurrent influenza A (H1N1) infection and CIP, accompanied by persistent respiratory dysfunction and progressive pulmonary lesions.
Combined with the patient's immunotherapy history, respiratory symptoms, imaging changes, and positive influenza A (H1N1) etiological results, a final diagnosis of concurrent CIP and H1N1 viral pneumonia was established.
The patient initially received antiviral and empirical antibiotic therapy. Due to ongoing clinical deterioration and poor response to anti-infective treatment, glucocorticoids were reinitiated to target CIP after comprehensive evaluation.
The patient showed early radiographic worsening and intractable respiratory failure with no response to initial anti-infective management. After glucocorticoid administration, clinical symptoms and pulmonary lesions improved significantly, achieving a favorable recovery.
Isolated antiviral and antibiotic treatment may fail to control disease progression in patients with concurrent CIP and influenza A pneumonia. Timely and rational glucocorticoid use can reverse clinical deterioration and improve prognosis even in the setting of active viral infection. This case provides practical evidence for the individualized management of overlapping CIP and viral pneumonia.

PMID:
42888550
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement